A retrospective multicentre study (N=139) reports that a transition time <30 days when switching from natalizumab to an anti-CD20 agent is optimal for efficacy and safety (Bsteh et al. Eur J Neurol 2025;32:e16587). Mean age of patients at the time of switch was 38.8 years; median duration on natalizumab was 4.4 years. Read More